SAHPRA Recall on Compounded GLP-1 Medications: What Patients Should Know

SCOPE Certified Weight Loss Doctors

Start your journey

Key Takeaways

Selected compounded GLP-1 medications have been recalled by SAHPRA due to compliance concerns in certain supply chains.
GLP-1 treatment remains available in South Africa, and not all products are affected.
Patients should confirm if their medication is part of the recall and seek clinical advice if unsure.
Safe, regulated options are still available through registered pharmacies with appropriate oversight.
Clinicians can assist with reviewing treatment and arranging a safe transition if needed.

View our treatment options

What's in this article

SAHPRA Regulatory Update on Compounded GLP-1 Medications in South Africa

What this means for GLP-1 patients

Continued access through verified, compliant pharmacies

Start or continue your GLP-1 treatment safely

Speak to a clinician

SAHPRA Regulatory Update on Compounded GLP-1 Medications in South Africa

Recent regulatory communication from the South African Health Products Regulatory Authority (SAHPRA), in collaboration with the South African Pharmacy Council (SAPC), has raised concerns regarding compounded GLP-1 medicines supplied in South Africa following inspections at iDexis in Pretoria.

SAHPRA noted “concerns relating to quality, safety, and regulatory compliance” within parts of the supply chain and confirmed that selected compounded semaglutide and tirzepatide products were included in a regulatory recall. The regulator further stated that the “manufacture, importation, advertising, and distribution of unregistered medicines may pose a risk to public health,” with investigations currently ongoing. (SAHPRA Official Statement)

This development has raised questions among patients using GLP-1 therapies for medical weight management and metabolic health, particularly regarding continuity of treatment and sourcing of regulated alternatives.

What this means for GLP-1 patients

If you are currently using a compounded GLP-1 medication, it is important to confirm:

Whether your product is part of the
SAHPRA recall
Whether it was dispensed through a
fully registered and compliant compounding pathway
Whether ongoing treatment should be reviewed or adjusted by a clinician

Importantly, GLP-1 therapy remains available in South Africa. The current regulatory focus relates to specific supply chains and compliance processes, rather than all compounded GLP-1 treatments.

Continued access through verified, compliant pharmacies

At Get Tested, patient safety and regulatory compliance remain our highest priority.

We continue to support appropriate patients with access to compounded GLP-1 medications through registered South African compounding pharmacies that meet strict quality and governance standards.

All partner pharmacies are required to demonstrate:

Registration with South African regulatory authorities
Compounding strictly under individual prescriptions
Verified sourcing of pharmaceutical-grade active ingredients
Sterile compounding environments and controlled processes
Full documentation, traceability, and quality assurance systems

Start or continue your GLP-1 treatment safely

We offer a structured, fully supported program for patients seeking GLP-1 therapy:

✔ Online consultation with a qualified medical provider

✔ Individual clinical assessment for GLP-1 suitability

✔ Access to compounded semaglutide or tirzepatide where appropriate

✔ Dispensing through verified, registered compounding pharmacies

✔ Ongoing monitoring and clinical follow-up

View our treatment options

Speak to a clinician

If you are currently affected by the SAHPRA GLP-1 recall or are unsure about your current medication source, our clinical team can assist with a safe and compliant transition plan.

Book a consultation today to continue your treatment with confidence, clinical oversight, and regulatory compliance.